This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent article that appeared in the ARCHIVES, Frank and coworkers¹ claimed that retinopathy and excessive retinal vascular endothelial growth factor production in galactosemic rats were inhibited by the administration of an aldose reductase inhibitor (ARI). These retinal abnormalities, being a result of the experimental galactosemia, should have been expected to be least severe in whichever animals happen to be least severely galactosemic, as judged, eg, from a comparison of their glycated hemoglobin levels. The mean glycated hemoglobin level in the 5 galactosemic rats given the ARI was found to be only about half the level found in the control galactosemic rats not given the drug; moreover, the level seems to be not statistically significantly greater than the level in normal (nongalactosemic) animals.

Because the size of each of the experimental groups was small and because the glycated hemoglobin levels varied greatly among the 5 ARI-treated rats (coefficient of . . . [Full Text of this Article]